San Diego, United States
AnaptysBio is a clinical-stage biotechnology company that has been crafting its legacy since its founding in 2005. Specializing in the discovery and development of innovative immunology therapeutics, the company's mission is succinctly captured in its slogan: "Transforming patient health by delivering innovative immunology therapeutics."
Operating within the burgeoning industries of Biotechnology, Health Care, and Health and Wellness, AnaptysBio boasts a broad portfolio of immune cell modulators that include two promising checkpoint agonists currently in clinical development. Their focus is on significantly enhancing the quality of life for those battling autoimmune and inflammatory diseases.
Notably headquartered in the United States, AnaptysBio last captured investor attention during its Series D investment totaling $40.00M on 15 July 2015. This infusion was supported by a consortium of reputable investors, including HBM Healthcare Investments, Frazier Healthcare Partners, Cormorant Asset Management, Biotechnology Value Fund, and BioMed Ventures. The company's innovative trajectory positions it as a compelling investment opportunity in the realm of cutting-edge healthcare solutions.
